BRIEF—China identifies drugs that should have generic versions

China's National Health Commission has listed 34 drugs that it sees as in need of generic version.

Among them, there are:

Tracleer (bosentan) from Actelion, now part of the Janssen/Johnson & Johnson group of pharma companies, to treat pulmonary artery hypertension;

Faslodex (fulvestrant) from AstraZeneca to treat metastatic breast cancer; and

Pfizer's migraine headache drug Relpax (eletriptan).

The listed drugs are either facing patent expirations or clinical shortages in China, the Commission stated.